Avifavir® is the first effective drug for COVID‐19 treatment registered in Russia
AVIFAVIR®
ANTI COVID-19 THERAPY
Avifavir is the first Favipiravir-based drug in the world approved for the treatment of COVID-19. Favipiravir-based drugs have demonstrated efficacy in three independent clinical trials in Russia involving more than 700 patients with confirmed cases of COVID-19, as well as in trials conducted in Japan and other countries. The European Medical Alliance is the authorized representative of the Russian pharmaceutical company Chromis LLC, a joint venture (JV) of the Russian Direct Investment Fund (RDIF), the Russian State Welfare Fund, with the ChemRar Group, aimed at the production of Avifavir® and other related innovative antiviral drugs.Together with our founders, we represent interests in the regions of Europe, Latin America, Asia and Africa.
Benefits in everything
FOR PATIENTS
- efficient and safe
- both in hospitals and at home
- prevention of hospitalization
- faster recovery
- reduced contagiosity and isolated period
- convenient per os
- both in hospitals and at home
- prevention of hospitalization
- faster recovery
- reduced contagiosity and isolated period
- convenient per os
FOR DOCTORS
- no fear of COVID-19
- decreased burden on hospitals by 3 times
- reduced hospitalization period by 30
- decreased burden on hospitals by 3 times
- reduced hospitalization period by 30
FOR ECONOMY
- reduced social tensions
- reduced disability period
- support of economy
- prevention of lockdown
- reduced disability period
- support of economy
- prevention of lockdown
Avifavir® status by today
A brief history of the development of Avifavir® in the period 2020-2021 Today Avifavir® is registered in 15 countries of the world. The situation changes daily. Avifavir® has entered the international market and the European Medical Alliance is actively involved in this.
AVIFAVIR®
status by today
MAY 2020
Emergency Use Authorization obtaining via fast-track on 60 patients
JUNE 2020
AUGUST 2020
OCTOBER 2020
NOVEMBER 2020
MARCH 2021
AVIFAVIR®
advantages
Avifavir® advantages
Fully developed and scaled technology of API and DP manufacturingHigh quality of the product: 2 years stabilityProprietary IPClinical results efficacy in COVID-19 treatment 460 patients in 35 medical centers of Russia took part in clinical trials (phase II / III) of Avifavir®Fast supply of drug products to any destination 600 000+ packs per month manufacturing at 3 sites in RussiaOption for technology transfer to local partner for a long-term collaborationCompetitive pricing
Experts’ opinions
The drug proved to be highly effective during the clinical trials involving I.M. Sechenov First Moscow State Medical University, Lomonosov Moscow State University and other medical and academic institutions.Avifavir was first developed and licensed as commercial drug by ChemRar Group with the support of the Russian Direct Investment Fund and the Ministry of Industry and Trade of Russia. The permanent Marketing Authorization was obtained based on the clinical trial data covering 460 patients, which proved the drug’s ability to block the replication mechanisms of coronavirus, alleviate symptoms and reduce the duration of the disease by half compared to the conventional therapy. This clinical trial has been conducted in 35 medical centers across Russia.
Avifavir is one of the two registered drugs against coronavirus in the world. It is also the first drug against coronavirus registered in Russia, having demonstrated efficacy in clinical trials. Its inclusion in the guidelines for the prevention, diagnosis and treatment of coronavirus will allow patients across the country to receive therapy using the most effective drug currently available in Russia, as well as preventing the Russian healthcare system from being overwhelmed by the reduction in recovery time.
Kirill Dmitriev
CEO of the Russian Direct Investment FundChromis, the joint venture established by RDIF and ChemRar Group, along with all other citizens of the Russian Federation, received a welcome present for National Unity Day – a permanent registration for Avifavir, which is the first drug in the world to be registered for use in fighting the novel coronavirus infection. The highly effective drug will now be available not only in hospitals, but also for outpatient use. The provision of additional funding from the state for the purchase of outpatient drugs for use in combating the coronavirus infection will also mean that people will continue to receive the drug free of charge not only in hospitals, but also through medical prescriptions for use as a home treatment
Andrey Ivaschenko
Chairman of ChemRar GroupAvifavir has shown efficacy in the combined treatment of patients hospitalized with the new coronavirus infection, especially in improving their physical condition. The Ministry of Healthcare of Russia approved the permanent Marketing Authorization of Avifavir, so this drug can now be used both in the outpatient and inpatient conditions from the very first days of the disease
Bulat Bakirov
Doctor of Medicine, ProfessorThe entire presentation
Within the shortest term possible, the ChemRar specialists developed testing platforms and a set of methods for the synthesis of substances and pharmaceutical formulation. On May 29th, 2020, after all the pre-clinical and clinical studies were completed, the medicine was registered and became available to patients.We present to your attention the presentation of Avifavir. If necessary, you can download our files and read them in more detail. We have selected all the answers to your questions.
Description in PDF files
For your convenience, you can view the presentation files in any browser without downloading them. To download files to your device, you need to click the arrow in the right corner, enlarge the file and download from our file store.
PRESENTATION AVIFAFIR
Read / downloadFOR MEDICAL USE OF AVIFAVIR
Read / downloadSCIENCE SPOTLIGHT AVIFAFIR
Read / downloadABOUT CHEMRAR GROUP
Read / downloadINFORMATION LETTER
Read / downloadBRIEFING
NOTE
Read / downloadAcquisition of Avifavir and cooperation with us
We are interested in working with public and private companies to promote Avifavir worldwide.
AVIFAVIR®
Our instructions in 4 steps
The first step
Read the description of Avifavir in our introductory presentations.
The second step
The third step
The final step
About Us
EurMA®
www.eurma.eu
Summary
We are professional corporate consultants specializing in healthcare, pharmaceutical and medical technology companies. We analyze markets, plan new product launches and support investment decisions in the CIS and Central Asia.
Benefits
Geography
Expertise
Our team
Igor BerezovskyiCEO EurMAoffice@eurma.eu
Russia, CIS, Balkans, Latin America
Thomas RiegerCEO Solarkiosk Solutions GmbH thomas.rieger@solarkiosk.eu
Germany, Switzerland, Africa
Vasil KrumovCEO VS Delta Investment LLPinfo@vsinvestment.com
Arab region, Asia, Greece